Status:
RECRUITING
Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.
Lead Sponsor:
Aalborg University Hospital
Conditions:
Arthritis, Rheumatoid
Arthritis, Psoriatic
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inf...
Detailed Description
Tumor necrosis factor inhibitors (TNFIs) have been uses with success since 1999 in Denmark in treatment of various inflammatory diseases, eg. rheumatoid arthritis (RA), Chrohn's disease, psoriasis, ps...
Eligibility Criteria
Inclusion
- Patients \> 18 years
- Diagnosed with RA, PsA or AS.
- Starting treatment with infliximab or adalimumab.
- Co- treatment with csDMARD or glucocorticoid is acceptable.
- No new bDMARD is initiated at the time of sampling.
Exclusion
- \-
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04731831
Start Date
August 1 2020
End Date
December 30 2025
Last Update
June 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of rheumatology
Aalborg, Denmark, 8000